COVID-19: High prevalence found in Cape Town antibody study
Initial results from a seroprevalence survey conducted in the Cape Town Metro indicate that 37% of pregnant women and 42% of people living with HIV have tested positive for COVID-19 antibodies. The overall seroprevalence for the 2 700 public healthcare users whose blood samples were tested in the survey was 40%.
The presence of antibodies in people’s blood sample shows that they had been infected by Sars-CoV-2, the virus that causes COVID-19, and while this indicates some degree of immunity it does not necessarily mean they will be protected from the virus if reinfected. Although clinical studies are ongoing, there is no certainty of how much protection antibodies offer or for how long.
The prevalence of antibodies was higher in more densely populated Cape Town Metro sub-districts such as Khayelitsha and Klipfontein which researchers say suggests a high proportion of people in poorer communities have been exposed to and infected with Sars-CoV-2, which is consistent with previously reported infection and fatality rates.
Professor Mary-Ann Davies, a public health medicine specialist with the Centre for Infectious Disease Epidemiology and Research at the University of Cape Town, during a Western Cape government press briefing yesterday, said that although there is still a lot of uncertainty about antibody protection it’s unlikely that in the short term, there will be “explosive outbreaks” in previous hot spots or high density, most vulnerable communities which have experienced high morbidity and mortality.
She says the results suggest there is some level of immunity, but there are people in these communities like the elderly and people with co-morbidities who have shielded themselves during the last five months and who are still susceptible to infection. “There is also a lot of difference across the city and across the province and there will still be population subgroups where people would be vulnerable to future outbreaks. So vigilance is critical to make sure we are able to detect a second wave,” Davies said.
Results cannot be generalised
Davies cautioned that the study only gave a snapshot, or a broad insight into the dynamic of the epidemic, and could not be generalised to the wider population. It was limited in that blood samples were only from people who use public sector health facilities, did not include young and elderly patients, and were from a specific socio-economic group (HIV is more prevalent in poorer areas). “It cannot tell what proportion of the wider population has been infected,” she said.
Only the blood samples of healthy pregnant women, who attend antenatal visits at provincial facilities and people living with HIV who go to public sector clinics for routine care and who did not have COVID-19 symptoms were tested in the study. Anonymised blood samples were taken from July and early August. The results of the antibody tests were not shared with the people who provided the blood samples.
Davies said that prevalence varied from 30% to 46% across different sub-districts in the metro. Prevalence for different age groups (all between 20 and 60) fell into a relatively narrow range of 36% to 43%.
The preliminary results also found that seroprevalence was higher in women than in men, something researchers will investigate further.
The pharmaceutical company, Roche made the antibody test used in the study. Davies said that the test, recently authorised by the South African Health Products Regulatory Authority (SAHPRA) for COVID-19 surveillance, has a sensitivity of 90% and a specificity of 99%. This means that out of every 100 people who have had COVID-19 it will correctly diagnose 90 people, and for every 100 people who have not had COVID-19 it will produce one false positive. The findings presented on Thursday were not adjusted to account for these test performance issues.
Questioned on the test’s accuracy, Davies said the “low sensitivity of the test may mean we are slightly under-detecting the proportion of people who have been infected”. She also pointed out that people with asymptomatic infection may mount less of an antibody response and people who had been infected a long time ago, may not be detected because antibody response wanes over time.
“In the confirmed COVID-19 patients we tested, however, we found that the antibody responses were quite well maintained, up to about three months after infection,” Davies said.
She pointed out that a study published on Tuesday in the New England Journal of Medicine looking at serology in Iceland, found that the majority of patients continued to have antibodies for at least four months after their initial infection. “So, if anything, we probably are underestimating slightly,” she said.
According to Davies, the seroprevalence study results were not surprising as they fitted in with the number of deaths seen, particularly in the communities that have been worst affected. The results also fitted in with the epidemic which had seen a reduction in the number of cases, in spite of easing restrictions and coming out of a hard lockdown. “So, it appears that some degree of immunity is contributing to that,” she said.
Davies said that the study’s value is that it is good for monitoring trends. “So, if we test (other pregnant and HIV people) in a month or a few months’ time, we can tell “what is happening over time” or comparisons can be made with what is happening in other places. “Ideally we would like to test a sample of the people that represent the whole population in our province.” But, she says, this takes time.
The provincial health department intends to have more community serological surveys as part of its surveillance and containment strategy. This strategy seeks to pick up any upsurges in new cases and to contain them until a vaccine becomes available.
A national seroprevalence survey ran by the National Institutes for Communicable Disease and the Human Sciences Research Council is also expected to start soon.
*Adele Baleta is an independent science writer, WHO vaccine safety communications advisor and Internews pandemic mentor.